Skip to main content
Erschienen in: Journal of General Internal Medicine 10/2017

20.06.2017 | Original Research

Incidence and Predictors of Repeat Bone Mineral Densitometry: A Longitudinal Cohort Study

verfasst von: Emily C. White VanGompel, MD, MPH, Peter Franks, MD, John A. Robbins, MD, MHS, Joshua J. Fenton, MD, MPH

Erschienen in: Journal of General Internal Medicine | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Existing guidelines for repeat screening and treatment monitoring intervals regarding the use of dual-energy x-ray absorptiometry (DXA) scans are conflicting or lacking. The Choosing Wisely campaign recommends against repeating DXA scans within 2 years of initial screening. It is unclear how frequently physicians order repeat scans and what clinical factors contribute to their use.

Objective

To estimate cumulative incidence and predictors of repeat DXA for screening or treatment monitoring in a regional health system.

Design

Retrospective longitudinal cohort study

Participants

A total of 5992 women aged 40–84 years who received initial DXA screening from 2006 to 2011 within a regional health system in Sacramento, CA.

Main Measures

Two- and five-year cumulative incidence and hazard rations (HR) of repeat DXA by initial screening result (classified into three groups: low or high risk of progression to osteoporosis, or osteoporosis) and whether women were prescribed osteoporosis drugs after initial DXA.

Key Results

Among women not treated after initial DXA, 2-year cumulative incidence for low-risk, high-risk, and osteoporotic women was 8.0%, 13.8%, and 19.6%, respectively, increasing to 42.9%, 60.4%, and 57.4% by 5 years after initial screening. For treated women, median time to repeat DXA was over 3 years for all groups. Relative to women with low-risk initial DXA, high-risk initial DXA significantly predicted repeat screening for untreated women [adjusted HR 1.67 (95% CI 1.40–2.00)] but not within the treated group [HR 1.09 (95% CI 0.91–1.30)].

Conclusions

Repeat DXA screening was common in women both at low and high risk of progression to osteoporosis, with a substantial proportion of women receiving repeat scans within 2 years of initial screening. Conversely, only 60% of those at high-risk of progression to osteoporosis were re-screened within 5 years. Interventions are needed to help clinicians make higher-value decisions regarding repeat use of DXA scans.
Literatur
1.
Zurück zum Zitat U.S. Preventive Services Task Force. Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2011;154:356–364.CrossRef U.S. Preventive Services Task Force. Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2011;154:356–364.CrossRef
2.
Zurück zum Zitat Morris CA, Cabral D, Cheng H, et al. Patterns of Bone Mineral Density Testing: Current Guidelines, Testing Rates, and Interventions. J Gen Intern Med. 2004;19(7):783–790.CrossRefPubMedPubMedCentral Morris CA, Cabral D, Cheng H, et al. Patterns of Bone Mineral Density Testing: Current Guidelines, Testing Rates, and Interventions. J Gen Intern Med. 2004;19(7):783–790.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Lenchik L, Kiebzak GM, Blunt BA. What is the role of serial bone mineral density measurements in patient management? J Clin Densitom. 2002;5 Suppl:S29–38.CrossRefPubMed Lenchik L, Kiebzak GM, Blunt BA. What is the role of serial bone mineral density measurements in patient management? J Clin Densitom. 2002;5 Suppl:S29–38.CrossRefPubMed
4.
Zurück zum Zitat North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(1):25–54.CrossRef North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(1):25–54.CrossRef
5.
Zurück zum Zitat Bell KJ, Hayen A, Macaskill P, et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ. 2009;338:b2266.CrossRefPubMedPubMedCentral Bell KJ, Hayen A, Macaskill P, et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ. 2009;338:b2266.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Watts NB, Lewiecki EM, Bonnick SL, et al. Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res. 2009;24(10):1643–1646.CrossRefPubMed Watts NB, Lewiecki EM, Bonnick SL, et al. Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res. 2009;24(10):1643–1646.CrossRefPubMed
8.
Zurück zum Zitat Gourlay ML, Fine JP, Preisser JS, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366(3):225–233.CrossRefPubMedPubMedCentral Gourlay ML, Fine JP, Preisser JS, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366(3):225–233.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Hillier TA, Stone KL, Bauer DC, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167(2):155–160.CrossRefPubMed Hillier TA, Stone KL, Bauer DC, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167(2):155–160.CrossRefPubMed
10.
Zurück zum Zitat Berry SD, Samelson EJ, Pencina MJ, et al. Repeat bone mineral density screening and prediction of hip and major osteoporotic fracture. JAMA. 2013;310(12):1256–1262.CrossRefPubMedPubMedCentral Berry SD, Samelson EJ, Pencina MJ, et al. Repeat bone mineral density screening and prediction of hip and major osteoporotic fracture. JAMA. 2013;310(12):1256–1262.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Yazdany J, Schmajuk G, Robbins M, et al. Choosing wisely: the American College of Rheumatology’s Top 5 list of things physicians and patients should question. Arthritis Care Res. 2013;65(3):329–339.CrossRef Yazdany J, Schmajuk G, Robbins M, et al. Choosing wisely: the American College of Rheumatology’s Top 5 list of things physicians and patients should question. Arthritis Care Res. 2013;65(3):329–339.CrossRef
12.
Zurück zum Zitat Morden NE, Schpero WL, Zaha R, Sequist TD, Colla CH. Overuse of short-interval bone densitometry: assessing rates of low-value care. Osteoporos Int. 2014;25(9):2307–2311.CrossRefPubMedPubMedCentral Morden NE, Schpero WL, Zaha R, Sequist TD, Colla CH. Overuse of short-interval bone densitometry: assessing rates of low-value care. Osteoporos Int. 2014;25(9):2307–2311.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Amarnath AL, Franks P, Robbins JA, Xing G, Fenton JJ. Underuse and Overuse of Osteoporosis Screening in a Regional Health System: a Retrospective Cohort Study. J Gen Intern Med. 2015;30(12):1733–1740.CrossRefPubMedPubMedCentral Amarnath AL, Franks P, Robbins JA, Xing G, Fenton JJ. Underuse and Overuse of Osteoporosis Screening in a Regional Health System: a Retrospective Cohort Study. J Gen Intern Med. 2015;30(12):1733–1740.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom. 2013;16(4):455–466.CrossRefPubMed Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom. 2013;16(4):455–466.CrossRefPubMed
16.
Zurück zum Zitat Wang PS, Walker A, Tsuang M, Orav EJ, Levin R, Avorn J. Strategies for improving comorbidity measures based on Medicare and Medicaid claims data. J Clin Epidemiol. 2000;53(6):571–578.CrossRefPubMed Wang PS, Walker A, Tsuang M, Orav EJ, Levin R, Avorn J. Strategies for improving comorbidity measures based on Medicare and Medicaid claims data. J Clin Epidemiol. 2000;53(6):571–578.CrossRefPubMed
17.
Zurück zum Zitat Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16 Suppl 3:1–37.CrossRefPubMedPubMedCentral Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16 Suppl 3:1–37.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int. 2005;16(7):842–848.CrossRefPubMed Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int. 2005;16(7):842–848.CrossRefPubMed
19.
Zurück zum Zitat Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004;7(3):255–261.CrossRefPubMed Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004;7(3):255–261.CrossRefPubMed
20.
Zurück zum Zitat Nelson HD, Morris CD, Kraemer DF, et al. Osteoporosis in postmenopausal women: diagnosis and monitoring. Evid Rep Technol Assess (Summ). 2001(28):1–2. Nelson HD, Morris CD, Kraemer DF, et al. Osteoporosis in postmenopausal women: diagnosis and monitoring. Evid Rep Technol Assess (Summ). 2001(28):1–2.
Metadaten
Titel
Incidence and Predictors of Repeat Bone Mineral Densitometry: A Longitudinal Cohort Study
verfasst von
Emily C. White VanGompel, MD, MPH
Peter Franks, MD
John A. Robbins, MD, MHS
Joshua J. Fenton, MD, MPH
Publikationsdatum
20.06.2017
Verlag
Springer US
Erschienen in
Journal of General Internal Medicine / Ausgabe 10/2017
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-017-4094-y

Weitere Artikel der Ausgabe 10/2017

Journal of General Internal Medicine 10/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.